All News #Library
Others
Gilead passes on fully acquiring Pionyr, as eyes now turn to Tizona
23 Mar 2023 //
ENDPTS
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265
07 Nov 2022 //
BUSINESSWIRE
Pionyr doses first subject in Phase Ib cancer antibody trial
21 Sep 2022 //
CLINICALTRIALSARENA
Pionyr to Present on Myeloid Tuning Platform and TREM1 Targeting Ab Program
16 Jun 2022 //
BUSINESSWIRE

Market Place
Sourcing Support